Omega Therapeutics (OMGA)
(Real Time Quote from BATS)
$2.31 USD
+0.45 (24.19%)
Updated Jun 18, 2024 02:48 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
OMGA 2.31 +0.45(24.19%)
Will OMGA be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for OMGA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OMGA
Omega Therapeutics, Inc. (OMGA) Reports Q1 Loss, Tops Revenue Estimates
Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings?
OMGA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Omega Therapeutics, Inc. (OMGA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
Other News for OMGA
Raymond James starts Omega at outperform, cites platform
Expert Ratings For Omega Therapeutics
Omega Therapeutics initiated with bullish view at Raymond James
Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer
Omega Pacific Receives OTCQB Approval